Please login to the form below

Not currently logged in
Email:
Password:

nusinersen

This page shows the latest nusinersen news and features for those working in and with pharma, biotech and healthcare.

Novartis buys gene therapy firm AveXis for $8.7bn

Novartis buys gene therapy firm AveXis for $8.7bn

Its antisense drug Spinraza (nusinersen) is being sold in the US for $750, 000 in the first year and $375, 000 thereafter and is predicted to become a $1bn-$2bn product

Latest news

More from news
Approximately 4 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch August 2016 Deal Watch August 2016

    95. Ionis (US). Biogen (US). Exercise option . Nusinersen, in phase III for treatment for spinal muscular atrophy.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kantar Health

Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech,...

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Infographics